Idorsia Launches Phase 3 Study for Lucerastat and Partners with Nxera Pharma

Key Facts

1Idorsia has launched the pivotal Phase 3 FAB-KLEAR study evaluating lucerastat for the treatment of Fabry disease.

2Idorsia signed a co-development and commercialization agreement with Nxera Pharma regarding the drug.

Idorsia has launched the pivotal Phase 3 FAB-KLEAR study to evaluate lucerastat for the treatment of Fabry disease. Benzinga reported that the company also signed a co-development and commercialization agreement with Nxera Pharma regarding the drug.

The study is designed to assess the potential for lucerastat to reduce kidney Gb3 accumulation, a primary driver of Fabry-related renal complications. This strategic partnership aims to share development costs and commercial risks as Idorsia moves the treatment into the final stage of clinical testing.